BTIG Reiterates Buy on Denali Therapeutics, Maintains $32 Price Target
Benzinga Newsdesk 11 months ago
NewsPrice TargetReiterationAnalyst Ratings
BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $32 price target.
BTIG analyst Thomas Shrader reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $32 price target.